



**OFFICE OF THE MONTANA STATE AUDITOR
MONTANA COMMISSIONER OF SECURITIES AND INSURANCE**

**Pharmacy Benefit Manager Aggregated
Rebate and Fee Transparency Report—2022 Data**

December 31, 2023

Pharmacy Benefit Manager Aggregated Rebate and Fee Transparency Report – 2022 Data¹

I. Background

Beginning in 2022, Mont. Code Ann. § 33-2-2407 requires all pharmacy benefit managers (PBMs) licensed in the state of Montana to provide detailed information to the Office of the Montana State Auditor, Commissioner of Securities and Insurance (CSI) related to business in the previous calendar year. This information is reported at the aggregate level for each health plan, plan sponsor, and workers' compensation insurance carrier covered by the PBM, as well as at the detailed claim level. This statute also requires CSI to provide a transparency report summarizing the public portion of this data on CSI's website.

Leif Associates, Inc., an actuarial consulting firm, reviewed, analyzed, and compiled the data submitted by the PBMs and as reflected in this report and Exhibit I.

II. Data Collection and Reporting

For this report, PBMs were required to submit transparency reporting information to CSI by July 1, 2023, for 2022 transactions. CSI provided a template to PBMs with the required data elements at both the aggregate and claim level. The items (and definitions) included in the template were based on Section 33-2-2407, MCA.

The required reporting applied to PBMs who are licensed by the state of Montana and whose functions fall under the authority of the CSI. The report excludes any PBM whose business in Montana solely includes self-funded employer plans covered under the Employee Retirement Income Security Act (ERISA). Any such PBM was given the option to submit "zero" reporting, subject to an accompanying justification for its exemption from the reporting requirements.

Summary of Responses from PBMs	
Total PBMs	23
Reports submitted	18
Zero reports submitted or reports not required (due to no business reported in 2022)	5

As required by Section 33-3-2407(6), MCA, the data has been deidentified to protect confidential information as defined therein and any trade secrets for which a PBM sought confidential treatment under Section 33-2-2407(4), MCA. This includes removing or deidentifying information that discloses:

1. The identity of a specific pharmacy benefit manager
2. The identity of a specific health carrier, plan sponsor, or workers' compensation insurance carrier
3. The prices charged for a specific prescription drug or class of drugs
4. The amount of any rebates provided for a specific prescription drug or class of drugs

CSI reviewed the data for each PBM for reasonableness and completeness. Potential issues identified through CSI's review were discussed with the applicable PBM. In some cases, revised datasets were provided, and only the most recent submissions are reflected in this report. However, the values shown are all "as reported" and have not been independently audited or verified.

Eighteen PBMs reported a total of \$268.6 million of Total Prescription Drug Spending across 153 health plans, plan sponsors, and workers' compensation plans.

III. Data Issues

1. For two PBMs, the claim level detail indicated substantially higher spending than the aggregated reporting. The CSI is in the process of following up with the PBMs in question to resolve these issues and may submit an amended report, if necessary. The values shown in the current report reflect the values as reported by the PBMs.
2. In one instance, the CSI elected to display a PBM's data in two separate reports in Exhibit I due to the PBM's unique transaction processing.
3. As part of the claim-level data, PBMs were required to report on spread pricing. This is a practice where a PBM charges payers more than the amount paid to a pharmacy for a medication and retains the additional "spread" as margin or profit. Of the 18 PBMs submitting non-zero reports, 14 reported some amount of spread pricing that accounts for 3.1% of total drug spending for those PBMs. The impact of spread pricing for individual PBMs is not indicated in this report.

Definitions of Terms

PBM Aggregated Rebate and Fee Transparency Report

Field Name	Field Definition
(A) Prescription Drug Spending	Dollar amount of prescription drug claim spent for the PBM's health carrier, plan sponsor, or workers' compensation insurance carrier
(B) Rebates	Dollar amount of all rebates that the PBM received for the PBM's health carrier, plan sponsor, or workers' compensation insurance carrier
(C) Rebates Passed to Enrollees	Dollar amount of rebates passed on by the PBM to the enrollees at the point of sale that reduced the enrollee's applicable deductible, copayment, coinsurance, or other cost sharing amount
(D) Rebates Passed to Employers	Dollar amount of rebates passed on by the PBM directly to employers covered by the PBM's health carrier, plan sponsor, or workers' compensation insurance carrier
(E) Direct and Indirect Fees from Plan	Dollar amount of administrative or other fees paid to the PBM by the PBM's health carrier, plan sponsor, or workers' compensation insurance carrier
(F) Direct and Indirect Fees from Other Sources	Dollar amount of fees paid to the PBM by sources other than the PBM's health carrier, plan sponsor, or workers' compensation insurance carrier (e.g., drug manufacturers)
(G) Retained Rebates Not Passed Through	Dollar amount of rebates received by the PBM that were not paid directly to enrollees, employers, or the PBM's health carrier, plan sponsor, or workers' compensation insurance carrier
(H) Retained Fees from Other Sources	Dollar amount of fees received by the PBM from sourced other than the PBM's health carrier, plan sponsor, or workers' compensation insurance carrier that were not passed through to the health carrier, plan sponsor, or workers' compensation insurance carrier
(I) Net Prescription Drug Spending	Dollar amount of prescription drug spending by the PBM net of retained rebates and fees Calculated as: $(A) - (B) + (E) + (G) + (H)$
(J) Aggregate Retained Rebates and Fees (%)	Percentage of total rebates and fees from all sources retained by the PBM and not passed through to enrollees, employers, or the PBM's health carrier, plan sponsor, or workers' compensation insurance carrier Calculated as: $[(E) + (G) + (H)] / [(B) + (E) + (F)]$

(K) Highest Retained Rebate (%)	The highest percentage of retained rebates across the PBM's health carriers, plan sponsors, or worker's compensation insurance carriers
(L) Lowest Retained Rebate (%)	The lowest percentage of retained rebates across the PBM's health carriers, plan sponsors, or worker's compensation insurance carriers
(M) Mean Retained Rebate (%)	The average percentage of retained rebates across the PBM's health carriers, plan sponsors, or worker's compensation insurance carriers

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: 00Q805GD

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$62,736,634	\$22,538,229	\$0	\$22,538,229	\$0	\$0	\$0	\$0	\$40,198,405
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
0.000%	0.000%	0.000%	0.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
No Additional Plan Fees	\$0	\$62,736,634	No Fees from Other Sources	\$0	\$62,736,634

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
TARGETED IMMUNOMODULATORS	\$12,430,998.17
ANTIDIABETICS	\$8,034,968.49
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$2,771,240.44
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	\$1,706,373.16
MULTIPLE SCLEROSIS AGENTS	\$1,228,409.83
ANTICOAGULANTS	\$901,082.62
DERMATOLOGICALS	\$831,897.21
THYROID AGENTS	\$733,802.87
ENDOCRINE AND METABOLIC AGENTS - MISC.	\$713,037.87
MIGRAINE PRODUCTS	\$404,121.31

Comments:

(1) The reported values do not include any revenue from fees, retained rebates, or spread pricing and the source of operating revenue is unclear. The CSI is in the process of following up with the PBM to clarify these issues.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)] / [(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: 6WWM5EGW5

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$26,575,577	\$5,626,051	\$0	\$5,588,864	\$2,637	\$579,929	\$37,187	\$566,511	\$21,555,861
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
9.766%	-4.519%	24.079%	0.661%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
Contracted claim administration fee	\$2,637	\$8,332,955	Rebate Manufacturer Administrative Fees, Pharmacy Transaction Fees	\$579,929	\$26,575,577

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
ANTIINFLAM.TUMOR NECROSIS FACTOR INHIBITING AGENTS	\$3,196,440.71
ANTINEOPLASTICS	\$2,868,267.14
ANTIHYPERGLYCEMICS	\$2,826,076.03
IMMUNOSUPPRESSANTS	\$2,439,575.39
SKIN PREPS	\$1,675,458.30
CNS DRUGS	\$1,443,607.84
PSYCHOTHERAPEUTIC DRUGS	\$1,274,534.81
ANTIARTHRITICS	\$1,120,415.60
CARDIOVASCULAR	\$1,052,812.99
ANTIVIRALS	\$1,039,994.77

Comments:

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)]/[(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: 9T4A6QH4

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$215,470	\$40,600	\$0	\$0	\$0	\$0	\$40,600	\$0	\$215,470
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
100.000%	100.000%	100.000%	100.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
No Additional Plan Fees	\$0	\$215,470	No Fees from Other Sources	\$0	\$215,470

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
Analgesics	\$51,428.71
Antimigraine Agents	\$51,012.58
Gastrointestinal Agents	\$23,412.59
Blood Products and Modifiers	\$22,232.62
Antidepressants	\$11,033.78
Respiratory Tract/Pulmonary Agents	\$10,020.69
Central Nervous System Agents	\$8,079.10
Sleep Disorder Agents	\$7,422.12
Anticonvulsants	\$6,455.24
Genitourinary Agents	\$6,349.82

Comments:

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)] / [(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: AKM29783

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$2,262	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$2,262
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
0.000%	0.000%	0.000%	0.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
No Additional Plan Fees	\$0	\$2,262	No Fees from Other Sources	\$0	\$2,262

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
SSRI AGONISTS	\$1,207.07
VACCINES	\$119.40
B-ADREN AGON	\$8.99
ANTIBACTERIALS	\$1.68
NONSTEROIDAL AN	\$0.51
ANGIOTEN 2 ANTG	(\$0.30)
ANTIFUNGALS	(\$0.30)
THYROID AGENTS	(\$0.30)
ADRENALS	(\$0.60)
MACROLIDES	(\$0.60)

Comments:

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)] / [(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: APT0VDWR

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$3,731,923	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$3,731,923
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
0.000%	0.000%	0.000%	0.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
No Additional Plan Fees	\$0	\$3,731,923	No Fees from Other Sources	\$0	\$3,731,923

Top 10 Therapeutic Drug Classes	Comments:
Drug Class	Paid to Pharmacy
ANALGESICS - OPIOID	\$673,377.78
ANTICONVULSANTS	\$231,986.28
ANTIASTHMATIC AGENTS	\$212,061.58
ANALGESICS - NSAIDS	\$171,664.76
MISC CARDIOVASCULAR AGENTS	\$160,517.81
ANTIDEPRESSANTS	\$115,284.45
ANTICOAGULANTS	\$101,258.86
MUSCULOSKELETAL THERAPY AGENTS	\$81,865.63
MIGRAINE PRODUCTS	\$81,624.89
ANTIDIABETIC AGENTS	\$66,464.33

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

Calculations:
 (I) = (A) – (B) + (E) + (G) + (H)
 (J) = [(E) + (G) + (H)] / [(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: CMJC8HJN

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$8,602	\$583	\$0	\$0	\$690	\$5	\$583	\$5	\$9,297
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
100.000%	100.000%	100.000%	100.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
Administrative Fees	\$690	\$8,602	Network Administration	\$5	\$8,602

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
ANTICONVULSANTS	\$5,775.40
ANALGESICS - OPIOID	\$2,566.24
ANALGESICS - ANTI-INFLAMMATORY	\$144.24
ANTIEMETICS	\$50.86
MUSCULOSKELETAL THERAPY AGENTS	\$36.81
ANTIDEPRESSANTS	\$7.98
ANTIFUNGALS	\$6.50
LAXATIVES	\$3.54
CEPHALOSPORINS	\$2.71
ANALGESICS - NonNarcotic	\$1.75

Comments:

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)] / [(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: D5FKHIMO

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$1,459,390	\$229,918	\$0	\$229,918	\$18,452	\$0	\$0	\$0	\$1,247,924
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
7.429%	0.000%	0.000%	0.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
Compensation for contractual services provided	\$18,452	\$1,459,390	No Fees from Other Sources	\$0	\$1,459,390

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
Blood Glucose Regulators	\$389,740.98
Respiratory Tract/Pulmonary Agents	\$103,717.87
Anti-obesity Agents	\$97,753.07
Central Nervous System Agents	\$82,950.31
Antimigraine Agents	\$68,729.86
Blood Products and Modifiers	\$66,347.99
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment	\$52,183.03
Cardiovascular Agents	\$40,532.33
Immunological Agents	\$35,602.40
Antipsychotics	\$33,253.58

Comments:

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)] / [(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: F1BOV55Q

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$139,524	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$139,524
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
0.000%	0.000%	0.000%	0.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
No Additional Plan Fees	\$0	\$139,524	No Fees from Other Sources	\$0	\$139,524

Top 10 Therapeutic Drug Classes		Paid to Pharmacy	Comments:
Drug Class			
ANALGESICS		\$7,749,939.79	(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing. (2) Spending from reported claim level detail is substantially higher than the aggregated reporting. The CSI is in the process of following up with the PBM to resolve these issues. Calculations: (I) = (A) – (B) + (E) + (G) + (H) (J) = [(E) + (G) + (H)]/[(B) + (E) + (F)]
CNS DRUGS		\$4,273,857.70	
PSYCHOTHERAPEUTIC DRUGS		\$2,784,755.87	
ANTIARTHRITICS		\$1,804,333.30	
ANESTHETICS		\$1,554,212.76	
ANTICOAGULANTS		\$1,307,272.79	
GASTROINTESTINAL		\$1,201,309.01	
ANTIASTHMATICS		\$1,158,085.23	
UNCLASSIFIED DRUG PRODUCTS		\$1,139,307.04	
ANTIVIRALS		\$1,115,351.35	

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: G7DAJEV9

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$59,337	\$9,011	\$0	\$0	\$0	\$0	\$9,011	\$0	\$59,337
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
100.000%	0.000%	100.000%	100.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
No Additional Plan Fees	\$0	\$59,337	No Fees from Other Sources	\$0	\$59,337

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$8,738.75
PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	\$6,618.84
MIGRAINE PRODUCTS	\$5,155.92
ANTICOAGULANTS	\$4,958.55
ANTIVIRALS	\$3,902.65
URINARY ANTISPASMODICS	\$3,403.36
ANALGESICS - OPIOID	\$2,562.38
ANTICONVULSANTS	\$1,594.97
ANALGESICS - ANTI-INFLAMMATORY	\$1,034.60
MUSCULOSKELETAL THERAPY AGENTS	\$703.03

Comments:

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)] / [(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: G89B6BYL

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$917,101	\$152,943	\$0	\$149,750	\$33,573	\$0	\$3,193	\$0	\$800,925
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
19.712%	2.080%	2.080%	2.088%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
Copay Maximizer Program Fee, PBM Administrative Fee	\$33,573	\$917,101	No Fees from Other Sources	\$0	\$917,101

Top 10 Therapeutic Drug Classes		Comments:
Drug Class	Paid to Pharmacy	None
GASTROINTESTINAL AGENTS > GASTROINTESTINAL AGENTS, OTHER	\$234,247.69	Calculations: (I) = (A) – (B) + (E) + (G) + (H) (J) = [(E) + (G) + (H)]/[(B) + (E) + (F)]
IMMUNOLOGICAL AGENTS > IMMUNOLOGICAL AGENTS, OTHER	\$230,117.04	
IMMUNOLOGICAL AGENTS > IMMUNOSUPPRESSANTS	\$86,607.35	
ANTINEOPLASTICS > MOLECULAR TARGET INHIBITORS	\$60,374.96	
CENTRAL NERVOUS SYSTEM AGENTS > MULTIPLE SCLEROSIS AGENTS	\$54,368.96	
ANTINEOPLASTICS > ANTIANGIOGENIC AGENTS	\$48,248.43	
BLOOD GLUCOSE REGULATORS > ANTIDIABETIC AGENTS	\$43,367.99	
BLOOD GLUCOSE REGULATORS > INSULINS	\$29,005.34	
RESPIRATORY TRACT/PULMONARY AGENTS > RESPIRATORY TRACT AGENTS, OTHER	\$19,672.87	
MISCELLANEOUS THERAPEUTIC AGENTS > MISCELLANEOUS THERAPEUTIC AGENTS	\$13,097.66	

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: OWF3LVPU

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$1,143,638	\$205,459	\$0	\$0	\$0	\$0	\$205,459	\$0	\$1,143,638
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
100.000%	0.000%	100.000%	100.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
No Additional Plan Fees	\$0	\$1,143,638	No Fees from Other Sources	\$0	\$1,143,638

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
ANALGESICS - OPIOID	\$402,064.97
MIGRAINE PRODUCTS	\$121,154.65
ANTICONVULSANTS	\$113,047.65
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$74,670.62
ANTIDEPRESSANTS	\$48,246.74
ANTIVIRALS	\$33,507.00
ANTICOAGULANTS	\$32,662.16
ULCER DRUGS	\$29,810.88
ANTIPSYCHOTICS/ANTIMANIC AGENTS	\$29,301.73
ANALGESICS - ANTI-INFLAMMATORY	\$28,584.89

Comments:

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)] / [(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: TVL1XHDD

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$253,815	\$99,864	\$4,422	\$0	\$30,778	\$18,377	\$49,155	\$18,377	\$252,260
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
65.971%	49.222%	49.222%	49.222%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
Admin Fee	\$30,778	\$253,815	Manufacturer Admin Fees and Transaction Fees	\$18,377	\$253,815

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
Immunological Agents	\$53,455.21
Respiratory Tract/Pulmonary Agents	\$29,791.92
Blood Glucose Regulators	\$20,588.61
Cardiovascular Agents	\$18,979.70
Hormonal Agents, Stimulant/Replacement/Modifying (Thyroid)	\$16,765.75
Antidepressants	\$15,857.44
Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)	\$12,412.72
Miscellaneous Therapeutic Agents	\$10,290.23
Central Nervous System Agents	\$9,168.10
Antibacterials	\$8,691.79

Comments:

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)] / [(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: UARAZ4B

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$5,320,481	\$1,219,961	\$0	\$1,023,876	\$115,790	\$0	\$196,085	\$0	\$4,412,395
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
23.348%	15.230%	20.846%	16.073%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
admin fee per rx	\$115,790	\$5,320,481	No Fees from Other Sources	\$0	\$5,320,481

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
Immunological Agents	\$1,767,469.40
Blood Glucose Regulators	\$1,160,706.17
Respiratory Tract/ Pulmonary Agents	\$484,369.60
Antineoplastics	\$379,567.44
Central Nervous System Agents	\$256,214.96
Dermatological Agents	\$215,618.90
Cardiovascular Agents	\$156,576.41
Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Modifiers)	\$96,198.64
Blood Products and Modifiers	\$96,109.06
Antidepressants	\$83,269.62

Comments:
None

Calculations:
 $(I) = (A) - (B) + (E) + (G) + (H)$
 $(J) = [(E) + (G) + (H)] / [(B) + (E) + (F)]$

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: UJMPATX0

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$527,687	\$16,653	\$0	\$16,653	\$0	\$0	\$0	\$0	\$511,034
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
0.000%	0.000%	0.000%	0.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
No Additional Plan Fees	\$0	\$527,687	No Fees from Other Sources	\$0	\$527,687

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
ANTIDIABETICS	\$104,100.58
ANTIVIRALS	\$90,173.62
PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	\$61,185.42
DERMATOLOGICALS	\$55,207.46
GASTROINTESTINAL AGENTS - MISC.	\$34,265.32
ANALGESICS - ANTI-INFLAMMATORY	\$27,565.70
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$20,642.65
CONTRACEPTIVES	\$13,492.16
VACCINES	\$13,058.19
ENDOCRINE AND METABOLIC AGENTS - MISC.	\$10,725.25

Comments:

(1) The reported values do not include any revenue from fees, retained rebates, or spread pricing and the source of operating revenue is unclear. The CSI is in the process of following up with the PBM to clarify these issues.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)] / [(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: VBPEGHNX

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$30,069,502	\$6,053,669	\$0	\$5,448,301	\$1,336,756	\$0	\$605,368	\$0	\$25,957,957
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
26.279%	10.000%	10.000%	10.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
Administrative fees	\$1,336,756	\$30,069,502	No Fees from Other Sources	\$0	\$30,069,502

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
ANTIINFLAM.TUMOR NECROSIS FACTOR INHIBITING AGENTS	\$4,119,720.33
ANTIHYPERGLYCEMICS	\$3,562,709.75
ANTINEOPLASTICS	\$2,023,472.79
IMMUNOSUPPRESSANTS	\$1,968,197.62
ANTIASTHMATICS	\$1,898,810.37
SKIN PREPS	\$1,761,047.37
ANTIARTHRITICS	\$1,733,917.52
UNCLASSIFIED DRUG PRODUCTS	\$1,412,849.73
CNS DRUGS	\$1,361,883.97
ANTICOAGULANTS	\$906,347.43

Comments:

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)]/[(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: X0ITTEUN

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$328	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$328
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
0.000%	0.000%	0.000%	0.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
No Additional Plan Fees	\$0	\$328	No Fees from Other Sources	\$0	\$328

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
Antiemetics, Miscellaneous	\$56.43
HMG-CoA Reductase Inhibitors	\$11.67
Anxiolytics, Sedatives, & Hypnotics Misc	\$0.00
Adrenals	\$0.00
Benzodiazepines	\$0.00
Centrally Acting Skeletal Muscle Relaxants	\$0.00
Nonsteroidal Anti-inflammatory Agents	\$0.00
Opiate Agonists	\$0.00
Proton-pump Inhibitors	\$0.00

Comments:

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)] / [(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: YQ5FUQS0

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$6,208,494	\$633,454	\$0	\$589,054	\$103,619	\$102,650	\$44,400	\$102,650	\$5,470,002
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
29.851%	5.252%	21.277%	7.009%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
Client Fees	\$103,619	\$6,208,494	Manufacturer Admin Fees/Click Fees	\$102,650	\$6,208,494

Top 10 Therapeutic Drug Classes	
Drug Class	Paid to Pharmacy
DISEASE-MODIFYINGANTIRHEUMATIC AGENTS	\$1,159,121.23
INCRETIN MIMETICS	\$719,566.20
SKIN AND MUCOUS MEMBRANEAGENTS, MISC.	\$432,204.77
INSULINS	\$425,850.82
IMMUNOMODULATORY AGENTS	\$322,744.74
ANTINEOPLASTIC AGENTS	\$304,636.76
CENTRAL NERVOUS SYSTEMAGENTS, MISC.	\$233,245.70
SODIUM-GLUC COTRANSPORT 2(SGLT2) INHIB	\$231,884.63
ANTICOAGULANTS	\$170,938.98
CORTICOSTEROIDS (RESPIRATORYTRACT)	\$164,347.74

Comments:

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)]/[(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: ZHM38ORW

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$6,619,781	\$2,307,694	\$0	\$2,307,694	\$0	\$11,980	\$0	\$11,980	\$4,300,107
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
0.516%	0.000%	0.000%	0.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
No Additional Plan Fees	\$0	\$6,619,781	No Fees from Other Sources	\$0	\$6,203,691

Top 10 Therapeutic Drug Classes	Comments:
Drug Class	Paid to Pharmacy
ANTIRHEUMATIC	\$7,215,023.32
SKIN AND MUCOUS	\$5,308,292.73
INCRETIN MIMETI	\$2,774,547.95
ANTINEOPLASTIC	\$2,573,348.40
INSULINS	\$1,644,567.99
IMMUNOMOD AGNTS	\$1,558,498.71
ANTIDIABETIC	\$1,490,479.64
AMPHETAMINES	\$1,262,308.66
ANTIRETROVIRALS	\$1,255,356.36
CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS	\$921,378.86

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

(2) Spending from reported claim level detail is substantially higher than the aggregated reporting. The CSI is in the process of following up with the PBM to resolve these issues.

Calculations:

(I) = (A) – (B) + (E) + (G) + (H)

(J) = [(E) + (G) + (H)] / [(B) + (E) + (F)]

Aggregated PBM Experience

Data for Publication on Commissioner's Website

Masked PBM Identifier: ZVR41OZO

Data Period: CY 2022

(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
Prescription Drug Spending	Rebates	Rebates Passed Through to Enrollees	Rebates Passed Through to Employers	Direct and Indirect Fees from Plan	Direct and Indirect Fees from Other Sources	Retained Rebates not Passed Through	Retained Fees from Other Sources	Net Prescription Drug Spending
\$122,583,230	\$43,389,611	\$0	\$43,389,611	\$2,684,562	\$6,615,896	\$0	\$0	\$81,878,180
(J)	(K)	(L)	(M)					
Aggregate Retained Rebates and Fee %	Lowest Retained Rebate by Plan	Highest Retained Rebate by Plan	Mean Retained Rebate All Plans					
5.095%	0.000%	0.000%	0.000%					

Summary of Direct and Indirect Fees Paid by Covered Plans			Summary of Direct and Indirect Fees from Other Sources		
Description of Fees Paid by Plan	Total Direct/Indirect Fees	Total Prescription Drug Spending	Description of Fees Paid by Other Sources	Total Direct/Indirect Fees	Total Prescription Drug Spending
Program management fees	\$2,684,562	\$122,583,230	Manufacturer admin fees	\$6,615,896	\$122,583,230

Top 10 Therapeutic Drug Classes	Comments:
Drug Class	Paid to Pharmacy
ANALGESICS - ANTI-INFLAMMATORY	\$9,576,348.21
HEMATOLOGICAL AGENTS - MISC.	\$7,242,841.82
ANTIDIABETICS	\$6,501,688.34
DERMATOLOGICALS	\$5,965,628.81
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	\$4,716,907.33
PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	\$3,114,341.67
RESPIRATORY AGENTS - MISC.	\$1,925,207.03
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$1,818,353.76
ANTIVIRALS	\$1,445,370.74
ANTICOAGULANTS	\$1,017,823.36

(1) Prescription Drug Spending in Column (A) includes additional cost due to spread pricing.

Calculations:
 (I) = (A) – (B) + (E) + (G) + (H)
 (J) = [(E) + (G) + (H)]/[(B) + (E) + (F)]